Publication
Title
Role of dendritic cells in HIV-immunotherapy
Author
Abstract
HIV remains one of the most important deadly infections today, due to the lack of a preventive vaccine and limited access to medical care in developing countries. In developed countries, antiretroviral therapy is available, but it can not eliminate the virus, implying that life-long therapy is necessary. Therefore, it is important that other strategies such as therapeutic vaccination will be developed to control virus replication or even eliminate the virus. The major obstacles towards such a strategy are the huge variability of the virus and the profound HIV-induced immune dysfunction. In this review we focus on dendritic cell based immunotherapies against HIV. To develop an efficient immunotherapy, several elements should be taken into account such as which antigen and loading strategy to use, how to deliver the immunogen, how to optimize the interaction between antigenic peptide and T cells and avoid tolerance. Clearly, to develop an immunotherapy to complement the effect of HAART, it is not sufficient to enhance T cell responses against a consensus sequence or against the prevailing plasma virus. Broad and potent immune responses are needed to suppress the entire quasispecies, including the latent reservoir, and to prevent any escape.
Language
English
Source (journal)
Current HIV research. - Hilversum
Publication
Hilversum : 2010
ISSN
1570-162X
DOI
10.2174/157016210791208631
Volume/pages
8 :4 (2010) , p. 310-322
ISI
000277909100005
Full text (Publisher's DOI)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 01.06.2010
Last edited 23.08.2022
To cite this reference